The authors found that a bispecific antibody that targets both HER2 and PRLR can increase the binding and internalization of HER2-targeted ADCs in vitro and in vivo, resulting in improved antitumor activity in preclinical models of HER2-positive breast and ovarian cancers. This evidence concerns the gene ERBB2 and ovarian cancer.